Robbie Marcus
Stock Analyst at JP Morgan
(3.89)
# 661
Out of 5,116 analysts
177
Total ratings
55.17%
Success rate
8.7%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Upgrades: Overweight | $90 → $100 | $86.85 | +15.14% | 7 | Dec 18, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $82 → $118 | $95.47 | +23.60% | 8 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $66 → $78 | $82.62 | -5.59% | 7 | Dec 5, 2025 | |
| MDT Medtronic | Maintains: Neutral | $90 → $100 | $96.52 | +3.61% | 12 | Nov 13, 2025 | |
| HTFL HeartFlow | Maintains: Overweight | $36 → $40 | $29.82 | +34.14% | 2 | Nov 13, 2025 | |
| CNMD CONMED | Maintains: Neutral | $58 → $52 | $40.80 | +27.45% | 8 | Nov 6, 2025 | |
| RXST RxSight | Maintains: Underweight | $8 → $9 | $10.93 | -17.66% | 6 | Nov 6, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $115 → $100 | $90.77 | +10.17% | 7 | Nov 6, 2025 | |
| CBLL CeriBell | Maintains: Overweight | $21 → $17 | $21.30 | -20.19% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Neutral | $90 → $75 | $67.57 | +11.00% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $12 → $13 | $12.62 | +3.01% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $16 | $17.18 | -6.87% | 3 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $16 | $16.02 | -0.12% | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $15 → $7 | $7.42 | -5.66% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $87.39 | +37.32% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $19.38 | +85.76% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $354.22 | +25.63% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $577.81 | +16.82% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $7.46 | +74.26% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $96.06 | +14.51% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $288.63 | +14.33% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $40.33 | -0.82% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $83.61 | +7.64% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $27.39 | +82.55% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $2.42 | +230.58% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $316.97 | -21.13% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.80 | +2.94% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $124.84 | -5.48% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $176.60 | -11.66% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $116.21 | -65.58% | 2 | May 5, 2020 |
Edwards Lifesciences
Dec 18, 2025
Upgrades: Overweight
Price Target: $90 → $100
Current: $86.85
Upside: +15.14%
Inspire Medical Systems
Dec 16, 2025
Maintains: Neutral
Price Target: $82 → $118
Current: $95.47
Upside: +23.60%
The Cooper Companies
Dec 5, 2025
Maintains: Neutral
Price Target: $66 → $78
Current: $82.62
Upside: -5.59%
Medtronic
Nov 13, 2025
Maintains: Neutral
Price Target: $90 → $100
Current: $96.52
Upside: +3.61%
HeartFlow
Nov 13, 2025
Maintains: Overweight
Price Target: $36 → $40
Current: $29.82
Upside: +34.14%
CONMED
Nov 6, 2025
Maintains: Neutral
Price Target: $58 → $52
Current: $40.80
Upside: +27.45%
RxSight
Nov 6, 2025
Maintains: Underweight
Price Target: $8 → $9
Current: $10.93
Upside: -17.66%
Zimmer Biomet Holdings
Nov 6, 2025
Downgrades: Neutral
Price Target: $115 → $100
Current: $90.77
Upside: +10.17%
CeriBell
Nov 5, 2025
Maintains: Overweight
Price Target: $21 → $17
Current: $21.30
Upside: -20.19%
DexCom
Oct 31, 2025
Maintains: Neutral
Price Target: $90 → $75
Current: $67.57
Upside: +11.00%
Oct 31, 2025
Maintains: Underweight
Price Target: $12 → $13
Current: $12.62
Upside: +3.01%
Oct 30, 2025
Maintains: Neutral
Price Target: $13 → $16
Current: $17.18
Upside: -6.87%
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $16.02
Upside: -0.12%
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $7.42
Upside: -5.66%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $87.39
Upside: +37.32%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $19.38
Upside: +85.76%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $354.22
Upside: +25.63%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $577.81
Upside: +16.82%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $7.46
Upside: +74.26%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $96.06
Upside: +14.51%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $288.63
Upside: +14.33%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $40.33
Upside: -0.82%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $83.61
Upside: +7.64%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $27.39
Upside: +82.55%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $2.42
Upside: +230.58%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $316.97
Upside: -21.13%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.80
Upside: +2.94%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $124.84
Upside: -5.48%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $176.60
Upside: -11.66%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $116.21
Upside: -65.58%